Most　photodynamic　therapy　(PDT)　paradigms　work　through　the　highly　O-2-dependent　type　II　photoreaction　to　generate　singlet　oxygen　(O-1(2)).　The　hypoxic　microenvironment　of　solid　tumors　severely　hampers　therapeutic　outcomes.　Here,　we　present　a　novel　design　that　could　transfer　the　photo-physical　and　photo-chemical　properties　of　traditional　phthalocyanine-based　photo-sensitizers　from　type　II　photoreaction　to　efficient　type　I　photoreaction　and　vibrational　relaxation-induced　photothermal　conversion.　These　features　enable　the　obtained　nanostructured　phthalocyanine　assemblies　(e.g.,　NanoPcAF)　to　display　excellent　phototherapies　under　both　normoxic　and　hypoxic　conditions.　Moreover,　NanoPcAF　has　a　high　level　of　accumulation　in　tumor　tissues　after　intravenous　injection,　and　94%　of　tumor　growth　is　inhibited　in　a　preclinical　model　at　a　NanoPcAF　dose　of　0.8　nmol　g(-1)　and　light　dose　of　300　J　cm(-2).